In primary Sjögren's syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages

  Delli, Konstantina ^a   Haacke, Erlin A ^a   Kroese, Frans G M ^a   Pollard, Rodney P ^a   Ihrler, Stephan ^b   Van Der Vegt, Bert ^a   Vissink, Arjan ^a   Bootsma, Hendrika ^a   Spijkervet, Frederik K L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Laboratory for Dermatohistology and Oral Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; B LYMPHOCYTE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSESSMENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; EUROPEAN LEAGUE AGAINST RHEUMATISM SJOGREN SYNDROME DISEAES ACTIVITY INDEX; HUMAN; INTERMETHOD COMPARISON; LYMPHOCYTE COUNT; OUTCOME ASSESSMENT; PAROTID GLAND; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SJOEGREN SYNDROME; SJOGREN SYNDROME RESPONSE INDEX;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; HUMANS; PAROTID GLAND; RITUXIMAB; SJOGREN'S SYNDROME;

EID: 84961825592     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209317     Document Type: Article

References (15)

1. Cornec D, Costa S, Devauchelle-Pensec V, et al. Do high numbers of salivary-gland infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjögren's syndrome? Ann Rheum Dis 2016;75:e33.
2. Delli K, Haacke EA, Kroese FG, et al. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann Rheum Dis 2016; Published Online First: 12 Jan 2016. doi: 10.1136/annrheumdis-2015-208304
3. Cornec D, Costa S, Devauchelle-Pensec V, et al. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome. J Autoimmun 2016;67:102-10.
4. Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 2016;75:382-9.
5. Costa S, Schutz S, Cornec D, et al. B-cell and T-cell quantification in minor salivary glands in primary Sjögren's syndrome: development and validation of a pixel-based digital procedure. Arthritis Res Ther 2016;18:21.
6. Cornec D, Devauchelle-Pensec V, Mariette X, et al. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology (Oxford) 2015;54:1699-708.
7. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis 2012;71:1297-302.
8. Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 2014;73:1393-6.
9. Meiners PM, Arends S, Meijer JM, et al. Efficacy of retreatment with rituximab in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2015;33: 443-4.
10. Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis 2014;73:472-4.
11. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
12. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab. A randomized trial. Ann Intern Med 2014;160:233-42.
13. Pijpe J, Kalk WWI, van der Wal JE, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2007;46:335-41.
14. Delli K, Dijkstra PU, Stel AJ, et al. Diagnostic properties of ultrasound of major salivary glands in Sjögren's syndrome: a meta-analysis. Oral Dis 2015;21:792-800.
15. Jousse-Joulin S, Milic V, Jonsson MV, et al. Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review. Rheumatology (Oxford) 2015; Published Online First: 14 Dec 2015. doi: 10.1093/rheumatology/kev385